46. Ricordi C, Fraker.C., Szust J, al-Abdullah I, Poggioli R, Kirelew T et al. Towards making every pancreas count: significant improvement in human islet isolation from marginal (older) donors following addition of oxygenated perflourocarbon to the cold storage solution. Amer J Transplantation 2002; 2(Suppl. 3):229.

47. Lakey JRT, Warnock GL, Shapiro AM, Korbutt GS, Ao Z, Kneteman NM et al. In-traductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant 1999; 8:285-292.

48. Linetsky E, Bottino R, Lehmann R, Alejandro R, Inverardi L, Ricordi. Improved human islet isolation using a new enzyme blend, Liberase. Diabetes 1997; 46(7):1120-1123.

49. Lakey JR, Helms LM, Kin T, Korbutt GS, Rajotte RV, Shapiro AM et al. Serine-protease inhibition during islet isolation increases islet yield from human pancreases with prolonged ischemia. Transplantation 2001; 72:565-570.

50. Brandhorst H, Brandhorst D, Brendel M, Hering BJ, Bretzel RG. Assessment of intracellular insulin contents during all steps of human islet isolation procedure. Cell Transplant 1998; 7:489-495.

51. Lake SP, Bassett PD, Larkins A, Revell J, Walczak K, Chamberlain J et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes 1989; 38 Suppl 1:143-145.

52. Hering BJ, Bretzel RG, Hopt UT, Brandhorst H, Brandhorst D, Bollen et al. New protocol toward prevention of early human islet allograft failure. Transplant Proc 1994; 26:570-571.

53. Alejandro R, Mintz DH, Noel J, Latif Z, Koh N, Russell E et al. Islet cell transplantation in type I diabetes mellitus. Transplant Proc 1987; 19(1 Pt 3):2359-2361.

54. Weimar B, Rauber K, Brendel MD, Bretzel RG, Rau WS. Percutaneous transhepatic catheterization of the portal vein: A combined CT- and fluoroscopy-guided technique. Cardiovasc Intervent Radiol 1999; 22:342-344.

55. Bingley PJ, Colman P, Eisenbarth GS, Jackson R, McCulloch DK, Riley WJ et al. Standardization of IVGTT to predict IDDM. Diab Care 1992; 15:1313-1316.

56. Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA et al. First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes. J Pediatr 2001; 138:244-249.

57. Geiger MC, Ferreira JV, Froud T, Caulfield A, Baidal D, Rothenberg L et al. Evaluation of metabolic control by continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus after islet cell transplantation. Amer J Transplantation 2002; 74[4(Suppl.)]:110.

58. Haffner SM, Gonzalez C, Miettinen H, Kennedy E, Stern MP. A prospective analysis of the HOMA model. Diab Care 1996; 19:1138-1141.

59. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diab Care 1998; 21:2191-2192.

60. Scharp DW, Lacy PE, Weide LG, Marchetti P, McCullough CS, Flavin K et al. Intraportal islet allografts: the use of a stimulation index to represent functional results [published erratum appears in Transplant Proc 1991;23:2702]. Transplant Proc 1991; 23:796-798.

61. Alejandro R, Lehmann R, Ricordi C, Kenyon NS, Angelico MC, Burke G et al. Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes 1997; 46:1983-1989.

62. Teuscher AU, Kendall DM, Smets YF, Leone JP, Sutherland DE, Robertson et al. Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 1998; 47:324-330.

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook

Post a comment